Cell line · CVCL_2481
HEL 92.1.7
Cancer cell line, Homo sapiens. Erythroleukemia. 13 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. HEL 92.1.7. Cell lines, record CVCL_2481. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_2481
On this page
Cell line
As Cellosaurus gives it.
- Name
- HEL 92.1.7
- Accession
- CVCL_2481
- RRID
- RRID:CVCL_2481
- Synonyms
- HEL92.1.7, HEL-92.1.7, HEL-92-1-7, HEL-92_1_7, HEL-92, HEL9217
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 30Y
- Category
- Cancer cell line
- Diseases
- Erythroleukemia (NCIt C7152); Acute erythroid leukemia (ORDO Orphanet_318)
- Derived from
- Peripheral blood (in situ)
- Cell type
- Erythroblast
- Parent
- HEL (CVCL_0001)
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers13
3 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. | Blood Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. | Cell Biosci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine. | Front Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed |
1 to 10 of 13
See all 13 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Parent | HEL | CVCL_0001 | Cell lines | |
| Derived from it | HEL 92.1.7 SOD2 KO clone 13 | CVCL_C0D1 | Cell lines | |
| Derived from it | HEL 92.1.7 SOD2 KO clone 5 | CVCL_C0D0 | Cell lines | |
| Derived from it | HEL/TGR | CVCL_4Z61 | Cell lines |
Cell banks6
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2481
GET https://conductscience.org/api/cell-lines/v1/CVCL_2481/problems